Daiichi returns TS23 rights to Translational Sciences

Daiichi Sankyo Co. Ltd. (Tokyo:4568) returned to Translational Sciences Inc. (Memphis, Tenn.) exclusive, worldwide rights for TS23. The companies partnered in 2015 to develop and commercialize the blood clot-dissolving antibody (see BioCentury, Oct. 19, 2015).

Daiichi said the move was part of a reprioritization of its pipeline. Under the partners' deal, Daiichi would have been responsible for clinical development after Phase Ia testing, which Translational Sciences has completed...